Publication | Open Access

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast CancerBreast CancerPharmacotherapyOncologyRadiation OncologyEndocrine-related Cancer